15,284 Shares in Novo Nordisk A/S (NYSE:NVO) Bought by Gallagher Capital Advisors LLC

Gallagher Capital Advisors LLC bought a new stake in Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 15,284 shares of the company’s stock, valued at approximately $1,315,000. Novo Nordisk A/S makes up approximately 1.0% of Gallagher Capital Advisors LLC’s investment portfolio, making the stock its 26th biggest holding.

Several other hedge funds also recently bought and sold shares of the company. Marco Investment Management LLC lifted its position in shares of Novo Nordisk A/S by 1.5% during the 3rd quarter. Marco Investment Management LLC now owns 6,702 shares of the company’s stock worth $798,000 after buying an additional 100 shares during the period. Carr Financial Group Corp raised its stake in Novo Nordisk A/S by 5.1% during the third quarter. Carr Financial Group Corp now owns 2,100 shares of the company’s stock worth $250,000 after acquiring an additional 101 shares in the last quarter. Menard Financial Group LLC lifted its holdings in shares of Novo Nordisk A/S by 0.8% during the third quarter. Menard Financial Group LLC now owns 12,283 shares of the company’s stock valued at $1,463,000 after acquiring an additional 102 shares during the period. Optimist Retirement Group LLC boosted its stake in shares of Novo Nordisk A/S by 4.3% in the 3rd quarter. Optimist Retirement Group LLC now owns 2,747 shares of the company’s stock valued at $327,000 after purchasing an additional 112 shares in the last quarter. Finally, Financial Counselors Inc. grew its holdings in shares of Novo Nordisk A/S by 1.1% in the 3rd quarter. Financial Counselors Inc. now owns 11,009 shares of the company’s stock worth $1,311,000 after purchasing an additional 115 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 1.0 %

Shares of NVO opened at $87.19 on Monday. The firm has a market capitalization of $391.25 billion, a price-to-earnings ratio of 26.50, a PEG ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a 52 week low of $77.82 and a 52 week high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The business’s fifty day moving average price is $84.91 and its two-hundred day moving average price is $104.86.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be given a dividend of $0.7874 per share. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s payout ratio is presently 47.72%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on NVO. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. BMO Capital Markets cut their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Morgan Stanley began coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.